Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049151 · ClinicalTrials.gov registry record · Phase 3
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
A Phase 3 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT02049151 is a Phase 3 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 35 participants.
The verdict
NCT02049151, a Phase 3 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a multi-center, double-blind, placebo-controlled, randomized, Phase 3 trial in subjects with unresectable stage III non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary concurrent chemo-radiotherapy (CRT), comparing overall survival (OS) time in subjects treated with tecemotide versus subjects treated with tecemotide-matching placebo.
Interventions
- DRUG Placebo
- DRUG Tecemotide
- DRUG Cyclophosphamide (CPA)
- DRUG Saline (sodium chloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049151
The ClinicalTrials.gov registry entry for NCT02049151 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02049151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049151 about?
NCT02049151 is a clinical study titled "Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer". This is a multi-center, double-blind, placebo-controlled, randomized, Phase 3 trial in subjects with unresectable stage III non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary concurrent chemo-radiotherapy (CRT), comparing overall su...
What is the current status of trial NCT02049151?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2014-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02049151?
The interventions under investigation include: Placebo (DRUG), Tecemotide (DRUG), Cyclophosphamide (CPA) (DRUG), Saline (sodium chloride) (DRUG).
Who is sponsoring clinical trial NCT02049151?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.